Pomalidomide 1, 2, 3 & 4 Mg Cipla 1 mg, 2 mg, 3 mg, 4 mg Capsule
PDF Leaflet Revision Date: March 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of relapsed and refractory multiple myeloma in adults.
Dosage (summary)
Starting dose: 4 mg/day orally on Days 1-21 of 28-day cycles.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding; teratogenic effects expected.
Key Drug Interactions
- CYP1A2 inhibitors (reduce dose by 50%)
- CYP3A4 inducers (monitor closely)
Contraindications
- Hypersensitivity to pomalidomide
- Pregnancy
- Breastfeeding
- Women of childbearing potential not meeting contraceptive requirements
- Males unable to comply with contraceptive measures
Common side effects
- Neutropenia
- Thrombocytopenia
- Fatigue
- Pneumonia
Counselling Points
- Use effective contraception during treatment
- Report any signs of infection or bleeding
- Avoid donating blood or semen during and after treatment
Serious warnings
- Severe life-threatening birth defects
- Risk of thromboembolism
- Progressive multifocal leukoencephalopathy (PML)
Important Disclaimer
The Pomalidomide 1, 2, 3 & 4 Mg Cipla 1 mg, 2 mg, 3 mg, 4 mg Capsule professional information leaflet below is the property of Cipla Medpro and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
